Brief: Intelligent Bio Solutions Completes Clinical Cut-Off Study
02/04/2026 14:49
April 2 (Reuters) - Intelligent Bio Solutions Inc INBS.O: INTELLIGENT BIO SOLUTIONS COMPLETES CLINICAL CUT-OFF STUDY, ADVANCES FDA 510(K) CLINICAL PROGRAM TARGETING MULTI-BILLION-DOLLAR U.S. DRUG SCREENING MARKET INTELLIGENT BIO SOLUTIONS INC: NOW INITIATED SECOND PHASE OF ITS CLINICAL STUDY PROGRAM INTELLIGENT BIO SOLUTIONS INC: EXPECTS TO COMPLETE METHOD COMPARISON AND USABILITY STUDY BY END OF JUNE 2026 INTELLIGENT BIO SOLUTIONS INC: COMPLETION OF INTERFERENCE STUDY IS ANTICIPATED BY END OF JULY 2026 Source text: ID:nGNX5gY6rl Further company coverage: INBS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelligent Bio Solutions
See all newsBrief: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth
Brief: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry
Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%
Intelligent Bio Solutions rise after clearing security tests ahead of FDA filing
Brief: Intelligent Bio Solutions Completes Clinical Cut-Off Study